Pre-made Telisotuzumab biosimilar ( Whole mAb ADC, anti-MET therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-559
Anti-MET therapeutic antibody (Pre-made Telisotuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Telisotuzumab vedotin, also known as ABBV 399 (ABBV-399; ABT 399), is a novel, first-in-class, investigational antibody-drug conjugate being developed by AbbVie comprised of the anti-c-Met antibody, ABT-700, directed against the cell surface glycoprotein mesothelia, conjugated to monomethyl auristatin E (MMAE) for the treatment of patients with solid tumors.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MET therapeutic antibody (Pre-made Telisotuzumab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Solid tumours|